EP0981543A1 - Procede de mise en evidence d'anticorps anti-vih et antigenes utilises a cet effet - Google Patents

Procede de mise en evidence d'anticorps anti-vih et antigenes utilises a cet effet

Info

Publication number
EP0981543A1
EP0981543A1 EP98928257A EP98928257A EP0981543A1 EP 0981543 A1 EP0981543 A1 EP 0981543A1 EP 98928257 A EP98928257 A EP 98928257A EP 98928257 A EP98928257 A EP 98928257A EP 0981543 A1 EP0981543 A1 EP 0981543A1
Authority
EP
European Patent Office
Prior art keywords
antigen
subtype
derived
isolate
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98928257A
Other languages
German (de)
English (en)
Inventor
Frederic Donie
Elke Faatz
Eva Hoess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of EP0981543A1 publication Critical patent/EP0981543A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • AS epitope region of amino acid
  • the invention further relates to antigens and antigen mixtures. whose components are derived from the env gene product gp41 of HIV1 subtype D or from gp41 of HIV1 subtype E, as well as their use for the detection of HIV antibodies and a reagent kit.
  • AIDS immunodeficiency syndrome
  • HIV1 and HIV2 are known as pathogens. Both strains are similar in terms of morphology. Cell tropism, interaction with the CD4 receptor of T cells, the in vitro cytopathic effect on CD4 cells, the general genomic structure and the ability to trigger the disease AIDS (Clavel, 1987, AIDS 1, 135-140). However, the degree of immunological relationship is low, so that HIV 1 -specific antibodies generally do not show any cross-reaction to HIV2.
  • HIV 1 subtype In addition to the most widespread HIV1 group M subtypes, another HIV 1 subtype, subtype O, is known (Myers et al, Los Alamos database, 1994; Sharp et al. AIDS Suppl. 8, S27-S42, 1994).
  • infections with HIV1 group M are predominant.
  • the individual HIV subtypes of group M despite their basic relationship to one another, have considerable sequence differences in some genomic areas, which lead to the fact that heterogeneities sometimes also exist at the protein level. For example, it can happen that HIV antibody detection, in which test components or antigens are present, which specifically react with HIVl subtype A, does not react with HIVl subtype B samples. This leads to false negative test results, which should be avoided in the interest of the patient.
  • EP-A-0 326 490 describes synthetic peptides for the detection of HIV antibodies which are derived from the gp41 region of HIV1 or the gp36 region of HIV2 (there called gp42). A complete determination of antibodies against different HIV1 subtypes, especially the predominant group M, is not possible with these peptides.
  • WO 95/33206 discloses an immunological method for the simultaneous detection of antibodies against gp41, gp36 and gag-p24.
  • the method works on the principle of the bridge test, as described, for example, in EP-A-0 280 211, in which two antigens bridge the antibody to be detected. One of the antigens is bound to a solid phase. The bridging antibody is detected using the label bearing the other antigen.
  • peptides are used as antigens which are derived from gp41 (HIVl) or gp36 (HIV2) and from HIVl gag-p24.
  • the disclosed peptide sequences for gp41 are derived from the HIVl subtypes O and B. A further determination of subtypes, which ensures that other HIV subtypes of group M are also detected reliably and with sufficient sensitivity, is not possible with this method.
  • French patent application FR-Al-2 730 493 describes polypeptides of the glycoproteins gpl20 and gp41 which are derived from the HIV1 strain MAD.
  • the HIVI strain MAD is presumably to be assigned to group M subtype D.
  • false-negative detection reactions are a problem in the detection of HIV infections due to the high variability of HIV.
  • an approach to this problem is not disclosed.
  • the task was therefore to provide an improved method for the detection of antibodies against HIV and in particular HIV1 subtypes.
  • This improved method should ensure that in particular the subtypes of the widespread group M are specifically and clearly identified.
  • the method according to the invention largely overcomes the disadvantages of the prior art, that is to say that with the method according to the invention samples of patients who are infected with HIV 1 subtypes of group M are detected more reliably. It has surprisingly been found that through the use of antigens. which originate from the env gene product gp41 and in particular from sequences of epitope regions I and II of gp41 of the various HIV1 subtypes, which enables more reliable detection of HIV infections with the subtypes of group M and subtype O.
  • the antigens are preferably used as a mixture of different antigens. This can reduce the risk of the hook effect in samples with a high antibody concentration, since there are usually some antigens with high affinity and some with weaker affinity in the mixture.
  • the method according to the invention also enables the use of defined antigen sequences.
  • the method according to the invention can be used in all test procedures familiar to those skilled in the art for the immunological detection of HIV infections and in particular for the detection of HIV antibodies. These include, for example, homogeneous and heterogeneous immunoassays. If the test is carried out homogeneously, there is no separation of solid and liquid phases after the reaction, ie the binding of antibody and analyte. Rather, the detection of the analyte in homogeneous test procedures is often based on the turbidity that occurs when the presence of the analyte creates a crosslinking of antibodies and antigens. These methods with turbidity measurement are also called turbidimetric methods.
  • the antigens can be multimeric antigens (so-called polyhaptens) are present, which are then cross-linked by the antibodies present in the sample in proportion to their concentration.
  • the antibody to be detected bridges a solid-phase-bound antigen with a labeled antigen. After the immunological reaction has taken place, the solid phase is separated from the liquid phase and the marking is determined in one of the two phases.
  • the level of the signal is a measure of the amount or concentration of the analyte (here the antibody).
  • a solid-phase-bound antibody traps the analyte.
  • a second labeled antibody also binds to the analyte.
  • the separation of solid and liquid phase and the detection of the marking is carried out analogously to the bridge test method.
  • the test routines described are not intended to restrict the immunological detection methods that are possible according to the invention, but rather to explain them clearly.
  • the method according to the invention is particularly preferably carried out according to the bridge test concept. Also particularly preferred are combined detection methods, so-called “combination tests”, in which the bridge test for the detection of specific antibodies and the sandwich method for the detection of specific antigens are used simultaneously.
  • HIV antibodies can be detected and at the same time, by using antibodies that are specific for one or more HIV antigens, HIV antigens can be detected using the sandwich method.
  • German patent application DE 197 09 762.6 describes a combination test which enables the simultaneous detection of HIV antigens and antibodies.
  • the detection method according to the invention is preferably used in the context of such a combined test.
  • the subject of patent application DE 197 09 762.6 is an immunological, preferably heterogeneous method for the detection of an HIV infection, in which the receptors R1 to R6 are used.
  • receptors R1 and R2 are used which specifically bind the HIV1-p24 and / or HIV2-p26 antigen to be determined.
  • One or more antigens from the env range of HIVl, HIV2 or HIVV-SubO are used as receptors R3 and R4 (g ⁇ l60.
  • Receptors R3 and R4 gp41 and / or gp36 or fragments thereof are used as receptors R5 and R6 one or more antigens from the pol or gag range of HIVl, HIV2, or HIV-SubO are used, which are not p24 or p26 Antigens from the pol range of HIV1, HIV2 or HIVV-SubO are preferably used as R5 and R6.
  • Reverse transcriptase (RT) is particularly preferably used as receptor R5 and R6, which is described in a later section in the present application
  • Antigens and antigen mixtures described in more detail are preferably used in such a combination test as receptors R3 and R4.
  • the inventive method of the present application can be carried out as a wet and dry test.
  • wet tests all test reagents are in the liquid phase.
  • all common dry test formats that are suitable for the detection of proteins or antibodies can also be used.
  • the test components are applied to a carrier.
  • the method according to the invention is preferably carried out as a wet test.
  • All biological fluids known to the person skilled in the art which are probably infected with HIV can be used as samples which are analyzed with the method according to the invention. be used.
  • Body fluids such as whole blood and blood serum are preferred as samples.
  • Blood plasma, urine, saliva etc. are used.
  • the antigens used in the process according to the invention are derived from the env gene product gp41 from HIVl.
  • the antigens. whose sequences are described in SEQ ID NO 1 to 7, and which are preferably used in the method according to the invention, derive from the so-called epitope regions I and / or II from gp41 for the various HIV1 subtypes. Some of the peptides can be assigned to epitope area II. The other part to epitope area I of gp41. These areas are particularly reactive immunologically. A comparison of the sequences in these areas shows that heterogeneities occur here with the different HIV1 subtypes. It has also been shown that, in particular with subtype D (epitope area II), greater sequence heterogeneities occur than with the other representatives of group M.
  • Table 1 shows the sequence variants of different HIV1 subtypes in epitope area II of gp41.
  • Table 2 shows the sequence variants of various HIV1 subtypes in epitope area I of gp41. The numbers below the sequences indicate the respective amino acid positions in gp41.
  • the invention further relates to antigens which are derived from epitope region II of gp41 of the HIV subtype D.
  • the antigens preferably correspond to the sequences from Table 3 or partial sequences thereof and are described in the sequence listing under the designation SEQ ID NO 1 to 6.
  • the invention further relates to antigens which contain partial sequences of the sequences SEQ ID NO 1-6 disclosed in Table 3 with a minimum length of 7 amino acids, the region being those between the two cysteines Amino acids including the two cysteines.
  • the two cysteines are mostly in the form of an intramolecular disulfide bridge. which creates a closed ring structure, i.e. a loop.
  • antigens which contain partial sequences of the sequences SEQ ID NO 1-6 with a minimum length of 10 amino acids disclosed in Table 3 are particularly preferred, the region comprising at least the amino acids located between the two cysteines, including the two cysteines, and three which are C-terminal subsequent amino acids.
  • Particularly preferred partial sequences correspond to the structure given in formula (I):
  • sequences can be flanked by further amino acids or modified by methods familiar to the person skilled in the art.
  • the only condition that must be met is. that the modified antigen is recognized and specifically bound by antibodies which are directed against the unmodified partial sequence.
  • the invention also relates to antigens which are derived from epitope region I of gp41Pl of the HIV subtype E.
  • the antigens preferably contain the sequence from Table 4 or partial sequences thereof with a minimum length of 6 amino acids and are described in the sequence listing under the name SEQ ID NO 12.
  • Table 4 Antigens from the Pl range from gp41 of HIV subtype E
  • Another object of the invention is therefore the use of an antigen according to SEQ ID NO 1 to 1 1 or partial sequences thereof and / or an antigen according to SEQ ID NO 12 or partial sequences thereof for the detection of antibodies against HIV, in particular of antibodies against HIV1 subtypes of Group M.
  • the use of antigen mixtures has proven to be particularly advantageous for the reliable detection of various HIV1 subtypes. It is advantageous if at least two different antigens, which are based on the sequence of different subtypes, are used in the detection method.
  • the invention therefore also relates to an antigen mixture consisting of at least two antigens, at least one antigen of gp41 of an HIV1 subtype D and at least one antigen being derived from the corresponding region of gp41 of another HIVV subtype of group M.
  • the antigen of gp41 of an HIV1 subtype D isolate preferably corresponds to epitope area II (AS 518-533) of the consensus D sequence, an antigen according to SEQ ID NO 1-1 1 being particularly preferably used.
  • the invention also relates to an antigen mixture consisting of at least one antigen derived from gp41 of an HIV1 subtype isolate and at least one antigen which is derived from the corresponding region of gp41 of another HIVV subtype of group M.
  • the antigen of gp41 of an HIV1 subtype E isolate preferably corresponds to epitope area I (AS 551-565) of the consensus E sequence, an antigen according to SEQ ID NO 12 being particularly preferably used.
  • the antigen mixture can also consist of antigens of epitope regions II and I of gp41.
  • the mixture then consists of at least one antigen derived from gp41 of an HIV1 subtype D isolate, preferably an antigen from epitope area II (AS 518-533) of the Consensus D sequence and particularly preferably an antigen according to SEQ ID NO 1- 11 is used, at least one antigen from the corresponding region of gp41 of another HIV subtype of group M, at least one antigen from gp41 of an HIV subtype E isolate, preferably an antigen from epitope region I (AS 551-565) Consensus E sequence and particularly preferably an antigen derived from SEQ ID NO 12 is used and at least one antigen derived from the corresponding region of gp41 of another HIV M subtype of group M consists.
  • Antigen mixtures are preferably used in which the antigen from epitope region II of gp41 of an HIV1 subtype D isolate of SEQ ID NO 1 to 6 or partial sequences thereof with a minimum length of 7 AS or SEQ ID NO 7 to 11 corresponds, and / or the antigen from epitope region I of gp41 of an HIV1 subtype E isolate of SEQ ID NO 12 or partial sequences thereof with a minimum length of 6 AS corresponds.
  • Another object of the invention is therefore also the use of one of the antigen mixtures described above for the detection of antibodies against HIV, in particular of antibodies against HIV1 subtypes of group M and subtype O.
  • the use of one may be necessary or several subtype O-specific antigens from epitope areas I or II of gp41 are necessary.
  • An additional antigen is particularly preferred in addition to the antigen mixtures described above. derived from epitope area II of gp41 of HIV subtype B and or an additional antigen derived from epitope area I of gp41 of HIV1 subtype B is used. Such an antigen mixture further improves the HIV1 subtype detection of group M considerably.
  • antigen mixtures described above are also preferred to the antigen mixtures described above.
  • Such an antigen mixture again improves the HIV1 subtype recognition, since both the recognition of group M subtypes and of subtype O can be ensured in one approach.
  • the following mixtures, which have proven to be advantageous in the determination of HIV subtypes, can be mentioned here by way of example and as preferred:
  • Subtype D LGIWGCSGKHICTTIV
  • Subtype O LSLWGCKGKLVCYTSV
  • Subtype B AVERYLKDQQLLGIW
  • Subtype O (Ant 70): ALETLLQNQQLLSLW
  • antigens from this area can also be used which recognize other HIV subtypes such as subtype A, C, F or G.
  • the only requirement is. that the test procedure itself still has to work. Should In the future, if other HIV subtypes are to be identified, it is self-evident for the person skilled in the art to use further antigens which are then derived from the env range of the respective subtype and preferably from the gp41 range.
  • antigens and antigen mixtures according to the invention can of course also be used for the production of antibodies or vaccines by methods familiar to the person skilled in the art.
  • the antigens used are not restricted to those antigens which are derived from HIV1 subtypes. In order to ensure reliable detection of HIV infections regardless of the virus strain, it is desirable to use, in addition to the antigens described in the env range of HIV1, antigens which are derived from the env range and in particular gp36 from HIV2.
  • the antigens and antigen mixtures according to the invention are derived from an HIV gene product from the env range, in particular from the gp41 and particularly preferably from the epitope range I and II of the gp41.
  • the amino acid sequence preferably corresponds to the naturally occurring sequence, since it can thus be ensured that the various subtypes are reliably detected using the immunological detection method. This means that the antibodies contained in the sample which are directed against a certain HIV1 subtype specifically bind these antigens. In the case of the bridge test, the antigens would have to be bridged by the antibody.
  • the term “antigen” is to be understood as a binding partner that specifically binds to an antibody with a corresponding binding site.
  • the antigen represents the epitope that is recognized and specifically bound by the antibody.
  • the antigen is preferably a peptide or protein, so it is preferred from amino acids, but can also be modified by sugar structures and / or lipid structures, provided that the antigenic properties of the antigen, ie the ability to bind to the antibody to be detected, are not significantly changed can of course also be used as pure peptides without further modifications.
  • the use of unmodified antigens is conceivable, for example, in competitive tests. In principle, all modifications of the antigens required for the respective test procedure and familiar to the person skilled in the art are permitted. It is always essential that the binding ability of the antigens to the specific antibodies to be detected is retained.
  • peptide antigens are used, it can be advantageous to modify the peptides.
  • a peptide which represents a specific epitope region can, for example, also have N-terminal and / or C-terminal flanking sequences which no longer correspond to the specific epitope.
  • the peptides can also contain epitope-foreign sequences that do not naturally occur in this amino acid connection.
  • the only requirement is that, despite the flanking amino acids, the epitopes of the peptide are still preserved.
  • the antibodies to be detected can specifically bind the respective epitope.
  • spacer groups familiar to the person skilled in the art. Again, the only condition here is that the ability to bind to the antibodies to be determined is retained.
  • the peptides or antigens can also be modified within the epitope range, for example by substitution, deletion or insertion of individual amino acid residues. However, the prerequisite for such changes is that the specific binding capacity of the antibodies to be detected is retained.
  • peptides and antigens according to the invention which correspond to a specific epitope of the env region and in particular of the epitope region I and II of the gp41 are also to be understood as peptide derivatives in which one or more amino acids have been derivatized by a chemical reaction.
  • peptide derivatives according to the invention are, in particular, those molecules in which the backbone and / or reactive amino acid side groups, for example free amino groups, free carboxyl groups and / or free hydroxyl groups, have been derivatized.
  • Specific examples of derivatives of amino groups are sulfonic acid or carboxamides, thiourethane derivatives and ammonium salts, for example hydrochlorides.
  • Carboxyl group derivatives are salts, esters and amides. Examples of hydroxyl group derivatives are O-acyl or O-alkyl derivatives.
  • the peptides are preferably prepared by chemical synthesis according to methods known to the person skilled in the art and do not require any special explanation here. In principle, the peptides and antigens can also be produced by means of recombinant methods. The claimed epitopes or antigens can be part of a larger recombinant protein.
  • peptide derivative also includes those peptides in which one or more amino acids are replaced by naturally occurring or non-naturally occurring amino acid homologs of the 20 “standard” amino acids.
  • homologs are 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine , Homoserine, ornithine, ⁇ -alanine and 4-aminobutyric acid
  • the peptide derivatives must have an essentially equivalent specificity and / or affinity for binding to the antibodies to be determined, such as the peptides or antigens from which they are derived.
  • Peptides or antigens according to the invention which correspond to a specific epitope are also understood to mean peptide-mimetic substances, hereinafter referred to as peptide mimetics, which have an essentially equivalent specificity and / or affinity for binding to the antibodies to be determined, such as the aforementioned peptides or peptide derivatives .
  • Peptide mimetics are compounds which can replace peptides in their interaction with the antibody to be determined and can have increased stability compared to the native peptides, in particular towards proteinases or peptidases. Methods for the production of peptide mimetics are described in Giannis and Kolter, Angew. Chem. 105 (1993), 1303-1326 and Lee et al., Bull. Chem. Soc. Jpn. 66 (1993), 2006-2010.
  • the length of an epitope is based on the naturally occurring epitopes of gp41.
  • the minimum length of an epitope is usually at least 4 to 6 amino acids. However, the length is preferably longer, that is to say between 6 and 20, and particularly preferably between 8 and 15 amino acids. In the case of peptide mimetics or peptide derivatives, an analogous length or size of the molecule is necessary.
  • the antigens according to the invention can be provided with solid-phase binding groups such as biotin and haptens such as digoxigenin and other labeling groups such as, for example, metal chelate complexes, by methods known to those skilled in the art. Methods for producing hapten-labeled peptides are described, for example, in WO 96/03423. Methods for producing metal chelate-labeled peptides are explained in WO 96/03651.
  • the antigens cannot be used alone or as a mixture of individual antigens, each antigen containing an epitope only once. It can often be advantageous if epitopes are present multiple times, i.e. as multiple epitopes. Such a multiple epitope is also called polyhapten. Polyhaptens are particularly suitable for the detection of specific IgM. WO 96/03652 discloses such polyhaptens and processes for their preparation. The coupling of such polyhaptens with labeling groups, haptens and solid-phase binding groups is also disclosed there.
  • the antigens according to the invention are preferably used as polyhaptens, the production process of which the person skilled in the art can easily see from WO 96/03652.
  • the invention further relates to a reagent for the detection of antibodies against HIV by means of an immunoassay consisting of a) at least one antigen from gp41 of an HIV1 subtype D isolate. preferably derived from epitope area II (AS 518-533) of the consensus D sequence and at least one antigen. which is derived from the corresponding region from gp41 of another HIV M subtype isolate from group M, and / or b) at least one antigen from gp41 of an HIV subtype E isolate, preferably derived from epitope region I (AS 551-565) the consensus E sequence and at least one antigen.
  • an immunoassay consisting of a) at least one antigen from gp41 of an HIV1 subtype D isolate. preferably derived from epitope area II (AS 518-533) of the consensus D sequence and at least one antigen. which is derived from the corresponding region from gp41 of another HIV M subtype isolate from group M, and / or b) at least one
  • test additives include, for example, buffers, salts, detergents. and auxiliaries such as Bovine serum albumin.
  • the necessary additives are known to the person skilled in the art or can be found out by him in a simple manner.
  • the corresponding partial sequences of the amino acid sequence of the HIV gp41 virus protein are synthesized by means of fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis on a batch peptide synthesizer, e.g. from Applied Biosystems A431 or A433.
  • Fmoc fluorenylmethyloxycarbonyl
  • the amino acids or amino acid derivatives are dissolved in N-methylpyrolidone.
  • the peptide is added to 400-500 mg of 4- (2 ', 4'-dimethoxyphenyl-Fmoc-aminomethyl) phenoxy- Resin (Tetrahedron Letters 28 (1987), 2107) with a loading of 0.4 - 0.7 mmol / g built up (JACS 95 (1973), 1328).
  • the coupling reactions are carried out with respect to the Fmoc amino acid derivative with 4 equivalents of dicyclohexylcarbodiimide and 4 equivaltenes of N-hydroxybenzotriazole in dimethylformamide as the reaction medium for 20 min.
  • the Fmoc group is split off with 20% piperidine in dimethylformamide in 20 min. If the peptides contain an intramolecular disulfide bridge, the Fmoc-protected peptide sequence is attached to the coupling of the artificial spacer with iodine in hexafluoroisopropanol / dichloromethane (Kober et al., The Peptide Academic Press, New York, 1981, pp 145-47) Oxidized solid phase and then cleaved the N-terminal Fmoc protective group, and the spacer and the N-terminal biotin or a bispyridyl-ruthenium complex coupled.
  • the release of the peptide from the synthetic resin and the cleavage of the acid-labile protective groups - with the exception of the phenylacetyl protective group on the lysine - is carried out with 20 ml trifluoroacetic acid, 0.5 ml ethanedithiol, 1 ml thioanisole, 1.5 g phenol and 1 ml water in 40 min at room temperature.
  • the reaction solution is then mixed with 300 ml of cooled diisopropyl ether and kept at 0 ° C. for 40 min to completely precipitate the peptide.
  • the precipitate is filtered off, washed with diisopropyl ether, dissolved in a little 50% acetic acid and lyophilized.
  • the raw material obtained is prepared by means of preparative HPLC on Delta-PAK RP Cl 8 material (column 50 ⁇ 300 mm, 100 ⁇ , 15 ⁇ ) over a corresponding gradient (eluent A: water, 0.1% trifluoroacetic acid. Eluent B: acetonitrile, 0.1% Trifluoroacetic acid) cleaned in about 120 min. The identity of the eluted material is checked by means of ion spray mass spectrometry.
  • Consensus B Antigen 1 Biotin XUZU L G I w G C (ox) S G K L I C (ox) T T A V
  • the peptide synthesis is carried out analogously to Example 1. If lysines are in the sequence, the amino acid derivative Fmoc-Lys (PhAc) -OH is used instead of Fmoc-Lys (Boc) -OH for the synthesis. The synthesis is ended after the N-terminal Fmoc protective group of the last spacer amino acid has been cleaved off. When the peptide is released from the synthetic resin and the acid-labile protective groups are split off, the phenylacetyl protective group on the lysine is not removed.
  • the digoxigenin or digoxin label is introduced via active ester derivatives (for example digoxigenin-3-carboxymethyl ether-N-hydroxysuccinimide ester) onto the free amino groups of the peptide in solution.
  • active ester derivatives for example digoxigenin-3-carboxymethyl ether-N-hydroxysuccinimide ester
  • the peptide to be derivatized is dissolved in a mixture of DMSO and 0.1 M potassium phosphate buffer pH 8.5. Then 2 equivalents of active ester per free primary amino function dissolved in a little DMSO are added dropwise and the mixture is stirred at room temperature. The turnover is followed by analytical HPLC. The product is purified using preparative HPLC.
  • the peptide still contains lysines protected with phenylacetyl, this protective group is cleaved in the last step enzymatically with immobilized PenG amidase in an aqueous medium with an organic solvent component at room temperature.
  • the immobilized enzyme is filtered off and the peptide is purified by preparative HPLC. The identity of the eluted material is checked by means of ion spray mass spectrometry.
  • the test was carried out analogously to the procedure described in the package insert for the Enzymun-Test ® Anti-HIV 1 + 2 + SubtypO (Order No. 1557319, Boehringer Mannheim GmbH, Germany). Only the antigen bottles 2a and 2b were exchanged for a peptide solution (amount of antigen used in each case 5 nmol / ml). All buffers and detection reagents were retained. The test was carried out at 25 ° C. on the ES 600 or ES700 (manufacturer: Boehringer Mannheim GmbH, Germany) in a sample volume of 100 ⁇ l in test tubes coated with streptavidin according to the principle of the 2-step sandwich ELISA. The following reagents were used:
  • Incubation buffer Tris 50 mM pH 7.5; Beef Serum Ingredients
  • Conjugate buffer Tris 50 mM pH 7.5; Beef Serum Ingredients
  • Substrate ABTS ® substrate solution (2,2'-azino-di [3-ethylbenzthiazoline sulfonate] 1.9 mmol / 1 in 100 mmol / 1 phosphate / citrate buffer, pH 4.4, sodium perborate 3.2 mmol /1
  • the use of the antigen mixture with antigens of different HIV subtypes proves to be advantageous compared to the use of the individual antigens:
  • the use of the antigen mixture leads to significantly earlier detection (at higher dilution) of infected samples, i.e. the sensitivity to dilution is positively influenced by the use of the antigen mixture.
  • infections with subtype B and subtype D can be detected more reliably.
  • Subtype B sera react with subtype B specific antigens in higher dilutions than with subtype D specific antigens.
  • subtype D sera with subtype D specific antigens react positively even when the sera is diluted to a greater extent, while they react weaker with subtype B specific antigens.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de mise en évidence d'anticorps anti-VIH à l'aide d'un immuno-essai, qui se caractérise en ce qu'on utilise au moins un antigène du produit génique-env gp41 d'un isolat-D du sous-type du VIH1 et au moins un antigène dérivé du gp41 d'un autre sous-type du VIH1 du groupe M, et/ou au moins un antigène du gp41 d'un isolat-E du sous-type du VIH1 et au moins un antigène dérivé du gp41 d'un autre sous-type du VIH1 du groupe M. L'invention concerne en outre des antigènes et des mélanges d'antigènes dont les constituants sont dérivés du gp41 d'un sous-type du VIH1 de l'isolat-D ou du gp41 du sous-type du VIH1 de l'isolat-E, ainsi que leur utilisation pour mettre des anticorps anti-VIH en évidence, de même qu'un kit de réactifs.
EP98928257A 1997-05-16 1998-05-13 Procede de mise en evidence d'anticorps anti-vih et antigenes utilises a cet effet Withdrawn EP0981543A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19720914A DE19720914A1 (de) 1997-05-16 1997-05-16 Verfahren zum Nachweis von HIV-Antikörpern und dazu verwendete Antigene
DE19720914 1997-05-16
PCT/EP1998/002816 WO1998052969A1 (fr) 1997-05-16 1998-05-13 Procede de mise en evidence d'anticorps anti-vih et antigenes utilises a cet effet

Publications (1)

Publication Number Publication Date
EP0981543A1 true EP0981543A1 (fr) 2000-03-01

Family

ID=7829888

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98928257A Withdrawn EP0981543A1 (fr) 1997-05-16 1998-05-13 Procede de mise en evidence d'anticorps anti-vih et antigenes utilises a cet effet

Country Status (10)

Country Link
US (1) US20030054336A1 (fr)
EP (1) EP0981543A1 (fr)
JP (1) JP2002511853A (fr)
CN (1) CN1263536A (fr)
AR (1) AR015659A1 (fr)
AU (1) AU8016998A (fr)
CA (1) CA2289679A1 (fr)
DE (1) DE19720914A1 (fr)
WO (1) WO1998052969A1 (fr)
ZA (1) ZA984100B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2839555B1 (fr) * 2002-05-10 2007-07-27 Bio Rad Pasteur Procede de detection simultanee d'un antigene et d'un anticorps d'un microorganisme infectieux
AU2007283186A1 (en) * 2006-08-08 2008-02-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Improved immunoassay involving mutant antigens to reduce unspecific binding
FR2987836A1 (fr) * 2012-03-09 2013-09-13 Biomerieux Sa Peptides d'interference et procede de detection de microorganismes
CN114605505B (zh) * 2018-08-09 2023-01-31 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502904A (ja) * 1986-03-24 1988-10-27 オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン 合成ｈｔｌｖ−３ペプチド、その組成物及び用途
AU641375B2 (en) * 1988-12-20 1993-09-23 Clarity Technologies Incorporated Synthetic HIV-like peptides, their compositions and uses
IE901427A1 (en) * 1990-07-23 1991-11-06 Prendergast Patrick T Treatment for viral interference
FR2730493B1 (fr) * 1995-02-09 1997-04-18 Pasteur Institut Polypeptides de glycoproteine transmembranaire d'enveloppe du retrovirus humain du type hiv-1 et polypeptides presentant avec eux une parente immunologique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9852969A1 *

Also Published As

Publication number Publication date
CA2289679A1 (fr) 1998-11-26
ZA984100B (en) 1999-11-15
AU8016998A (en) 1998-12-11
CN1263536A (zh) 2000-08-16
AR015659A1 (es) 2001-05-16
US20030054336A1 (en) 2003-03-20
DE19720914A1 (de) 1998-11-19
WO1998052969A1 (fr) 1998-11-26
JP2002511853A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
DE3588254T2 (de) GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DE3650175T3 (de) Synthetische antigene zum nachweis von aids.
EP0673948B1 (fr) Peptides dérivés d'un rétrovirus du groupe SIV et leur utilisation
EP0723551B1 (fr) Peptides marques par un haptene
DE69535601T2 (de) Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
EP0772774B1 (fr) Dosage d'une immunoglobuline specifique a l'aide de multiples antigenes
EP0770679B1 (fr) Peptides spécifiques pour HCV, préparations les contenant et leur utilisation
DE68929467T3 (de) HIV-2 Varianten
EP0591914A2 (fr) Rétrovirus du groupe HIV et son application
WO1996003423A9 (fr) Peptides marques par un haptene
DE69133242T2 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
EP0972198B1 (fr) Procede de detection simultanee d'antigenes de vih et d'anticorps de vih
DE69223250T3 (de) Detektion des immunschwäche-virus aus felis
DE60015312T2 (de) Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon
EP0922958B1 (fr) Réduction d'interférence dans les méthodes diagnostiques utilisants les peptides comportant les D-acides amines
DE68925043T3 (de) Synthetische Peptide und deren Mischungen für den Nachweis von HIV-Antikörpern
DE4430973A1 (de) Hapten-markierte Peptide
DE69325943T3 (de) Synthetische Polypeptide vom Hepatitis C-Virus, verwendbar für den Nachweis des Virus
EP0981543A1 (fr) Procede de mise en evidence d'anticorps anti-vih et antigenes utilises a cet effet
DE69836265T2 (de) Synthetische peptide für testverfahren zur bestimmung der infektion mit virus hiv1 der gruppe o
EP0732339B1 (fr) Peptides de la protéine gag d'HIV, leur procédé de préparation et leur utilisation
DE602005005999T2 (de) Modifizierte hiv-1-peptide und ihre verwendung beim nachweisen von anti-hiv-antikörper
DE69433057T2 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DE69635753T2 (de) Verbesserte hapten-peptidkonjugaten zum nachweis von anti-hiv-1 oder anti-hiv-2 antikörpern
DE19654764A1 (de) Verfahren zur Herstellung eines Peptidgemisches

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE ES FI FR GB IT LI NL

17Q First examination report despatched

Effective date: 20031203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040917